CA2155129A1 - Combinaisons d'inhibiteurs retroviraux - Google Patents

Combinaisons d'inhibiteurs retroviraux

Info

Publication number
CA2155129A1
CA2155129A1 CA2155129A CA2155129A CA2155129A1 CA 2155129 A1 CA2155129 A1 CA 2155129A1 CA 2155129 A CA2155129 A CA 2155129A CA 2155129 A CA2155129 A CA 2155129A CA 2155129 A1 CA2155129 A1 CA 2155129A1
Authority
CA
Canada
Prior art keywords
combinations
retroviral inhibitors
combination
retroviral
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2155129A
Other languages
English (en)
Other versions
CA2155129C (fr
Inventor
A. Stanley Tyms
Debra L. Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2155129A1 publication Critical patent/CA2155129A1/fr
Application granted granted Critical
Publication of CA2155129C publication Critical patent/CA2155129C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La combinaison d'esters de castanospermine et d'analogues peptidiques courts peut être utilisée dans le traitement des infections rétrovirales. La combinaison peut être utilisée pour traiter le sida et le para-sida et d'autres maladies provoquées par le rétrovirus VIH ou autres virus connexes.
CA002155129A 1993-02-22 1994-01-18 Combinaisons d'inhibiteurs retroviraux Expired - Fee Related CA2155129C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939303518A GB9303518D0 (en) 1993-02-22 1993-02-22 Combinations of retroviral inhibitors
GB9303518.6 1993-02-22

Publications (2)

Publication Number Publication Date
CA2155129A1 true CA2155129A1 (fr) 1994-09-01
CA2155129C CA2155129C (fr) 1999-04-13

Family

ID=10730826

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002155129A Expired - Fee Related CA2155129C (fr) 1993-02-22 1994-01-18 Combinaisons d'inhibiteurs retroviraux

Country Status (14)

Country Link
EP (1) EP0684836A1 (fr)
JP (1) JPH08509469A (fr)
KR (1) KR100293299B1 (fr)
CN (1) CN1118142A (fr)
AU (1) AU679497B2 (fr)
CA (1) CA2155129C (fr)
GB (1) GB9303518D0 (fr)
HU (1) HUT72493A (fr)
IL (1) IL108696A (fr)
MX (1) MXPA94001311A (fr)
NO (1) NO307738B1 (fr)
NZ (1) NZ261740A (fr)
WO (1) WO1994019008A1 (fr)
ZA (1) ZA941036B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2889014A1 (fr) 2005-07-22 2007-01-26 Nextamp Sa Procede et dispositif de tatouage d'horodates, procede et dispositif de decodage d'horodates, applications et produits programmes d'ordinateur correspondants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3526015A1 (de) * 1985-07-20 1987-01-22 Philips Patentverwaltung Verfahren zum bestimmen der raeumlichen verteilung der streuquerschnitte fuer elastisch gestreute roentgenstrahlung und anordnung zur durchfuehrung des verfahrens
US5004746A (en) * 1987-09-29 1991-04-02 Merrell Dow Pharmaceuticals Inc. Anti-retroviral castanospermine esters
US4999146A (en) * 1990-02-12 1991-03-12 Thermax Wire Corp. Process for manufacture of low density polytetrofluoroethylene insulated cable
EP0565631B1 (fr) * 1991-01-02 1996-09-18 Merrell Pharmaceuticals Inc. Composes antiviraux

Also Published As

Publication number Publication date
NO307738B1 (no) 2000-05-22
HU9502451D0 (en) 1995-10-30
IL108696A (en) 1999-06-20
MXPA94001311A (es) 2003-11-13
HUT72493A (en) 1996-05-28
GB9303518D0 (en) 1993-04-07
WO1994019008A1 (fr) 1994-09-01
AU6091894A (en) 1994-09-14
KR960700743A (ko) 1996-02-24
ZA941036B (en) 1994-08-25
NO953272L (no) 1995-08-21
NZ261740A (en) 1996-10-28
JPH08509469A (ja) 1996-10-08
CN1118142A (zh) 1996-03-06
KR100293299B1 (ko) 2001-09-17
EP0684836A1 (fr) 1995-12-06
CA2155129C (fr) 1999-04-13
IL108696A0 (en) 1994-05-30
AU679497B2 (en) 1997-07-03
NO953272D0 (no) 1995-08-21

Similar Documents

Publication Publication Date Title
MX9700237A (es) Combinaciones inhibidoras de proteasa retroviral.
BG102048A (en) Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors
AU697681B2 (en) Retroviral protease inhibiting compounds
CA2145661A1 (fr) Pyran-2-ones et 5,6-dihydropyran-2-ones utiles pour le traitement du hiv et d'autres retrovirus
CA2268709A1 (fr) Inhibiteurs de protease hiv
AU653972B2 (en) HIV protease inhibitors
AU2452288A (en) Nucleoside derivatives useful in treating retroviral infections
SG120493G (en) N-tert-Butyl-decahydro-2(3-amino-2-hydroxy-4-phenyl-butyl) isoquinoline-3-carboxamide and asparaginyl derivatives thereof
CA2075173A1 (fr) Composes et methodes pour inhiber le vih et les virus associes
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
AU1954392A (en) Inhibitors of hiv protease useful for the treatment of aids
AU667593B2 (en) Inhibitors of HIV protease useful for the treatment of AIDS
CA2168447A1 (fr) Composes et methodes pour l'inhibition du vih et de virus connexes
AU4135493A (en) Inhibitors of HIV protease useful for the treatment of AIDS
AU5252993A (en) Inhibitors of HIV protease useful for the treatment of AIDS
CA2195125A1 (fr) Agents antiviraux a base de difluorostatone
AU5491194A (en) Cytotoxic and antiviral compound
GR3024226T3 (en) Antiviral naphthoquinone compounds, compositions and uses thereof.
CA2285463A1 (fr) Therapie combinee des infections au vih
CA2155129A1 (fr) Combinaisons d'inhibiteurs retroviraux
EP0355409A3 (fr) L'utilisation d'un inhibiteur de prolylendopeptidase pour le traitement du SIDA
AU630249B2 (en) Prevention of glycoprotein enveloped virus infectivity by quinolyloxazole-2-ones
AU1296795A (en) Methods for preventing or treating hiv-1 or hiv-2 infection
IL112514A0 (en) Macrocyclic difluorostatone derivatives useful as antiviral agents
RU93055683A (ru) Ингибиторы вич-протеазы, способ их получения, их использование, композиция

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20060118